Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Curious about mushroom supplements? Here's what they do, what the science says, and how to know if they're right for ...

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles ...

Lipid receptor SR-B1 identified as a potential immunotherapy target to boost NK cell antitumor response in advanced ovarian cancer.

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing ...

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic ...

In this compelling episode of The Ellis Martin Report, host Ellis Martin engages in a powerful and enlightening conversation with Michael Breen, ...